Continental Advisors’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.04M | Buy |
36,700
+10,500
| +40% | +$871K | 1.43% | 22 |
|
|
2025
Q1 | $2.12M | Hold |
26,200
| – | – | 1.19% | 25 |
|
|
2024
Q4 | $2.36M | Buy |
26,200
+500
| +2% | +$45K | 1.09% | 22 |
|
|
2024
Q3 | $2.54M | Sell |
25,700
-2,500
| -9% | -$247K | 1.22% | 23 |
|
|
2024
Q2 | $2.61M | Buy |
28,200
+5,000
| +22% | +$464K | 1.15% | 24 |
|
|
2024
Q1 | $2.2M | Buy |
23,200
+1,500
| +7% | +$142K | 0.89% | 24 |
|
|
2023
Q4 | $1.94M | Sell |
21,700
-15,500
| -42% | -$1.38M | 0.76% | 25 |
|
|
2023
Q3 | $2.72M | Buy |
37,200
+1,500
| +4% | +$110K | 1.45% | 20 |
|
|
2023
Q2 | $2.97M | Sell |
35,700
-6,500
| -15% | -$541K | 1.34% | 18 |
|
|
2023
Q1 | $3.22M | Sell |
42,200
-3,800
| -8% | -$290K | 1.72% | 14 |
|
|
2022
Q4 | $3.82M | Buy |
46,000
+18,200
| +65% | +$1.51M | 2% | 11 |
|
|
2022
Q3 | $2.21M | Sell |
27,800
-5,500
| -17% | -$436K | 1.3% | 22 |
|
|
2022
Q2 | $2.47M | Buy |
33,300
+300
| +0.9% | +$22.3K | 1.49% | 17 |
|
|
2022
Q1 | $2.97M | Buy |
+33,000
| New | +$2.97M | 1.46% | 16 |
|